Infosheets

EU Defence Innovation Scheme (EUDIS)
Programmes EDF

Published on | 1 year ago

Last updated on | 4 months ago

Author Do you have an additional question? Or spotted a mistake? Don't hesitate to contact me!
Image of Mark Antonissen
Mark Antonissen

mark.antonissen@vlaio.be

The EU Defence Innovation Scheme (EUDIS) offers a set of instruments for small and medium-sized enterprises (SMEs), including start-ups, and other non-traditional players in defence industrial ecosystemto ensure more opportunities to access the European Defence Fund.

It aims to lower entry barriers into the defence domain for smaller players and innovators, focusing on technological readiness and market maturity.

EUDIS is here to support innovators throughout the development cycle to mature, scale-up, demonstrate their use-case, grow and successfully enter the market.

EUDIS Innovation Tracks

More information on the Innovation Tracks website.

  • Participate with your team in hackathons that will be held across Europe starting from spring 2024.
  • Organise or participate in technological challenges: set-up testing environments for Research & Development and compare your solution with competing teams.
  • Form a consortium and benefit from Innovation Test Hubs to distribute cascade funding grants to SMEs or start-ups.
  • Participate in spin-in calls: migrate your results from civil EU-funded R&D programmes to the defence sector.
  • Apply to the Defence Equity Facility: easier access to equity investments in Europe for the defence sector.
  • Take part in open SME and disruptive technologies calls: receive lump sum grants for R&D.
  • Benefit from business coaching: successful applicants to non-thematic SMEs and disruptive technologies calls can benefit from business coaching

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.